Kezar Life Sciences (KZR) Q4 2025 earnings summary

Executive summary

• Announced exploration of strategic alternatives after failing to align with FDA on a registrational trial for zetomipzomib in autoimmune hepatitis (AIH), leading to a major restructuring and workforce reduction of about 70%.

• Completed asset sale of Sec61-based program to Enodia Therapeutics, focusing remaining resources on zetomipzomib and strategic options.

• Zetomipzomib remains the only agent to show steroid-sparing activity in refractory AIH, with recent FDA feedback supporting a feasible clinical trial design.

Financial highlights

• Net loss for 2025 was $56.0 million, down from $83.7 million in 2024, reflecting reduced R&D and G&A expenses after restructuring.

• Accumulated deficit reached $490.5 million as of December 31, 2025.

• Cash and cash equivalents totaled $71.9 million at year-end 2025, expected to fund operations for at least 12 months.

• Research and development expenses decreased by $31.9 million year-over-year, primarily due to trial terminations and workforce reductions.

• General and administrative expenses decreased by $4.9 million year-over-year.

• Restructuring and impairment charges increased by $5.3 million due to severance and asset impairments.

Outlook and guidance

• Company is focused on maximizing stockholder value through potential strategic transactions, including mergers, acquisitions, or dissolution if no transaction is achieved.

• Operating expenses are expected to decrease further in 2026 due to ongoing cost containment and reduced development activity.

• Cash runway is projected to last at least 12 months under current plans.